Metoklopramid Hameln (Metoclopramide Hydrochloride Monohydrate)

Metoclopramide Hydrochloride antagonises dopamine D2 receptors in the chemoreceptor trigger zone, reducing the emetic signal, while also acting as a 5‑HT3 antagonist and 5‑HT4 agonist. These actions together promote gastric emptying and provide anti‑nausea effects.

The appropriate dose of Metoklopramid Hameln is determined by the prescribing clinician based on the patient’s condition, age, renal function and response to therapy. Dosage regimens are individualized and should follow the prescriber’s instructions.

Safety data for Metoklopramid Hameln in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

To order Metoklopramid Hameln, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Compared with other antiemetics such as ondansetron, Metoklopramid Hameln offers both dopamine antagonism and pro‑kinetic activity, making it useful for conditions involving delayed gastric emptying. However, it carries a higher risk of extrapyramidal side effects, so clinicians weigh benefits against potential risks for each patient.

Metoklopramid Hameln should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. Maintaining the cold‑chain ensures product stability and potency.

The product is supplied as an injectable solution for intramuscular or intravenous administration. The route, rate and duration of injection are determined by the prescribing clinician and should be performed by qualified healthcare personnel.

Serious risks include extrapyramidal symptoms such as dystonia, tardive dyskinesia with long‑term use, and neuroleptic malignant syndrome, a rare but life‑threatening condition. Patients should be monitored closely for any signs of these reactions.

Metoklopramid Hameln is contraindicated in patients with known hypersensitivity to metoclopramide or any component of the formulation, and it should be avoided in individuals with a history of severe extrapyramidal reactions or neuroleptic malignant syndrome.